ORIGINAL RESEARCH

Infectious Diseases

doi: 10.25005/2074-0581-2025-27-3-605-612
LOCAL IMMUNITY STATUS IN ADULT PATIENTS UNDERGOING TREATMENT FOR STREPTOCOCCAL TONSILLITIS IN THE CONTEXT OF CHRONIC EPSTEIN-BARR VIRAL INFECTION

T.B. RAKHMONOV1, D.A. VALISHIN1, R.S. FARSHATOV2

1Department of Infectious Diseases, Bashkir State Medical University, Ufa, Russian Federation
2Department of Therapy and Nursing with the Basics of Palliative Care, Bashkir State Medical University, Ufa, Russian Federation

Objective: The aim of the study was to assess the impact of treatment on local responses in patients with both streptococcal tonsillitis and chronic Epstein-Barr virus (EBV) infection, by analyzing changes in immune indicators within oropharyngeal secretions at early and advanced treatment stages.

Methods: A study was conducted involving 110 adult patients in the main group (MG) aged 18 to 67 years, who were hospitalized for moderate infectious mononucleosis (IM) and streptococcal tonsillitis. The control group (CG) consisted of 75 individuals, aged 18 to 65 years, who did not have IM or EBV, as confirmed by laboratory test results. Local immunity response in both groups was assessed by measuring the levels of lactoferrin, α-interferon-I, and tumor necrosis factor-α (TNF-α) in oropharyngeal secretions.

Results: The comparative analysis of lactoferrin levels between patients of the MG and the CG indicated that the lactoferrin level in patients with IM (4107.2±117.8 ng/mL) was significantly higher (p<0.05) than that in individuals in the CG (762.9±16.2 ng/mL). Similarly, the levels of α-interferon-I also showed a statistically significant difference between the MG and CG, with values of 27.1±1.4 pg/mL and 11.7±1.2 pg/mL, respectively (p<0.05). Fourteen days after admission, lactoferrin levels in MG patients changed insignificantly, going from 4107.2±117.8 ng/mL to 5457.8±132.6 ng/mL (p>0.05). However, the levels of α-interferon-I in MG patients showed a statistically significant decrease after 14 days, dropping from 27.1±1.4 pg/mL to 12.3±1.3 pg/mL (p<0.05). Initially, the average TNF-α levels in both the MG and CG patients were found to be within the normal range (0 to 10.0 pg/mL) and did not show a statistically significant difference. At the time of admission, the TNF-α level in the MG was measured at 9.96 [8.71; 11.21] pg/mL. After 14 days of treatment, this level had significantly decreased to 1.89 [1.57; 2.21] pg/mL (p<0.05).

Conclusion: Based on the study's results, a method was developed to assess the degree of immunological disorders. This method allows for monitoring the effectiveness of therapy for both IM in adults caused by EBV and streptococcal tonsillitis. Additionally, it enhances the accuracy of the prognosis regarding treatment outcomes.

Keywords: Streptococcal tonsillitis, infectious mononucleosis, Epstein-Barr virus, α-interferon-I, lactoferrin.

Download file:


References
  1. Baranova IP, Kurmaeva DYu, Lesina ON. Klinicheskie osobennosti infektsionnogo mononukleoza v zavisimosti ot vozrasta i etiologii zabolevaniya [Clinical features of infectious mononucleosis depending on age and etiology of the disease]. Infektsii. 2020;4:25-8.
  2. Karrera U, Nadalb D. Epstein-Barr-Virus und infektiöse Mononukleose. Schweiz Med Foru. 2019;11:226-32. https://doi.org/10.5167/uzh-96029
  3. Odumade OA. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiology Review. 2021;24(1):193-209. https://doi.org/10.1128/CMR.00044-10
  4. Ito Y. Cytomegalovirus and Epstein-Barr virus coinfection in three toddlers with prolonged illnesses. J Med Virol. 2019;81:1399-402. https://doi.org/10.1002/ jmv.21527
  5. Johanssen EC. Epstein-Barr virus (Infectious mononucleosis, Epstein-Barr virusassociated malignant diseases, and other diseases). Douglas and Bennett's Principles and Practice of Infectious Diseases. 2020;15:1989-2010. https://doi. org/10.1016/b978-0-443-06839-3.00139-9
  6. Ficher A. Severe immunodeficiencies. Clin Exp Immunol. 2020;2:143-9. https:// doi.org/10.1038/nrdp.2015.61
  7. Shestakova IV, Yushchuk ND. Sovremennye podkhody k lecheniyu Epshteyna- Barr virusnykh infektsiy u vzroslykh [Modern approaches to the treatment of Epstein-Barr virus infections in adults]. Lechashchiy vrach. 2021;2:64-8.
  8. Simovanyan EN, Sizyakina LP, Sarichev AM. Khronicheskaya Epshteyna-Barr virusnaya infektsiya [Chronic Epstein-Barr virus infection]. Doctor.Ru. 2022;2:34-42.
  9. Chesnokova NP. O roli nedostatochnosti rezistentnosti i spetsificheskikh immunologicheskikh mekhanizmov zashchity v patogeneze khronicheskogo sinusita [On the role of resistance insufficiency and specific immunological defence mechanisms in the pathogenesis of chronic sinusitis]. Saratovskiy nauchno-meditsinskiy zhurnal. 2017;4:40-3.
  10. Okano M. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol. 2015;80:64. https://doi.org/10.1002/ajh.20398
  11. Lyadova T, Popova A. Status of post-vaccination immunity to diphtheria and tetanus in adults with EBV infection. The Journal of V.N. Karazin Kharkiv National University, Series «Medicine». 2023;47:57-63. https://doi.org/10.26565/2313- 6693-2023-47-06
  12. Chen B, Han N, Gao LY, Zhou TD, Zhang H, He P, et al. Comparison of immune responses in children with infectious mononucleosis caused by Epstein-Barr virus at different infection stages. Int J Lab Hematol. 2023;45(6):890-8. https:// doi.org/10.1111/ijlh.14131
  13. Liu М. T cell-mediated immunity during Epstein-Barr virus infections in children. Infection, Genetics and Evolution. 2023;112:105443. https://doi.org/10.1016/j. meegid.2023.105443
  14. Keldyorova ZD. The state of cellular immunity in children with infectious mononucleosis. Texas Journal of Medical Science. 2022;15:24-6. https://doi. org/10.62480/tjms.2022.vol15.pp24-26
  15. Wang YY, Chen P. Research advances in infectious mononucleosis caused by Epstein-Barr virus. Open Journal of Pediatrics. 2024;14:108-21. https://doi. org/10.4236/ojped.2024.141012

Authors' information:


Rakhmonov Tursunboy Bakhtiyorovich,
Assistant, Department of Infectious Diseases, Bashkir State Medical University
ORCID ID: 0000-0003-4640-3879
E-mail: Tursunboy.r@gmail.com

Valishin Damir Askhatovich,
Doctor of Medical Sciences, Full Professor, of the Department of Infectious Diseases, Bashkir State Medical University Head
ORCID ID: 0000-0002-1811-9320
E-mail: damirval@yandex.ru

Farshatov Rasul Salikhovich,
Candidate of Medical Sciences, Associate Professor of the Department of Therapy and Nursing with the Basics of Palliative Care, Bashkir State Medical University
Researcher ID: J-4950-2013
ORCID ID: 0000-0002-5294-5263
SPIN: 8982-7125
Author ID: 567210
E-mail: rasulanesth03@mail.ru

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:


Rakhmonov Tursunboy Bakhtioyrovich
Assistant, Department of Infectious Diseases, Bashkir State Medical University

405103, Russian Federation, Ufa, Lenin str., 3

Tel.: +7 (905) 0055152

E-mail: Tursunboy.r@gmail.com


This work is licensed under a Creative Commons Attribution 4.0 International License.

Materials on the topic: